The auditorium, the largest venue of the event, was packed with an audience close to 1000 listening to speakers at both Richter-sponsored symposia.

The first symposium, co-organised with Recordati, examined the mood disorders associated with schizophrenia and how changes in serotonin and dopamine metabolism affect their development. At the second symposium, co-organised with Richter's US partner AbbVie, speakers discussed the potential of the transdiagnostic approach - a patient-centred, unified view of the symptoms of different psychiatric disorders. The transdiagnostic scale developed by experts at Richter Gedeon to quantify and visualise the symptom severity of patients with different psychiatric disorders was also presented for the first time to such a large audience.

"This is a very important multidisciplinary conference, an opportunity to create a dialogue between specialists in neurology, psychiatry and pharmacology. The transdiagnostic approach presented at the symposium also has a message for the lay public, as it can help to reduce the stigma associated with psychiatric drugs. From the patient’s viewpoint it has quite a different ring to it whether we talk about the need for regulating their dopamine metabolism, or the need to take a drug for schizophrenia," - said Dr Mária Judit Molnár, neurologist, psychiatrist and clinical geneticist, who was one of the speakers at the symposium.